Inovio Pharmaceuticals Inc vs First Trust Cloud Computing ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while First Trust Cloud Computing ETF trades at $163. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SKYY | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | — |
52-Week High | $2.87 | $161.09 |
52-Week Low | $0.66 | $104.16 |
Enterprise Value | $49.56M | — |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
SKYY (First Trust Cloud Computing ETF) trades at $162.56, up 1.11% with strong technical momentum as moving averages signal bullish sentiment. The ETF provides diversified exposure to cloud infrastructure, software, and AI companies, benefiting from secular trends in digital transformation. Recent news highlights institutional interest in cloud computing ETFs as AI adoption accelerates.
The outlook remains positive given cloud migration trends and AI infrastructure investments, though overbought technical indicators suggest potential near-term consolidation. Key risks include regulatory developments in Europe's tech sovereignty initiatives and competitive pressures in the cloud computing sector.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →